Skip to main content
Back to all tickers

Maison Solutions Inc. (MSS) stock forecast & analysis

2.10

NasdaqCM · USD

Up: +0.54, +34.6%

1 analysis

Use Arrow keys to explore price history; Home and End jump to the oldest and newest points
Price history for MSS.US from 08-25 13:00 to 09-24 12:36 with 1 analysis run marked; public runs are shown as stance-colored dots (Bullish, Bearish, or Neutral) and gated runs as a lock icon (sign in to read). Each marker is a link to sign in.BullishBearishNeutralLocked · sign in to read

Open
2.06
Previous close
1.56
Day range
1.81 – 2.95
52-week range
1.24 – 198.00
Volume (shares)
94.77M
Net assets
Not available
Expense ratio
Not available
Shares outstanding
810.54K
P/E ratio
Not available
Dividend yield
Not available
Beta
4.15
Market cap
1.83M
Market Scanner’s AI analysis of Maison Solutions Inc. (MSS), updated September 2026: Maison Solutions Inc. (MSS) faces declining revenue and net losses amidst volatile trading and positive news in colorectal cancer treatments.

This page is the public summary. A signed-in user can run a fresh five-stage AI analysis of Maison Solutions Inc. (MSS) and read the full verdict with the bull and bear debate behind it — using Market Scanner tokens, or their own OpenAI or Anthropic key.

Summary

Maison Solutions Inc. (MSS) faces declining revenue and net losses amidst volatile trading and positive news in colorectal cancer treatments.

Recent analyses for Maison Solutions Inc. (MSS) covered a significant year-over-year decrease in quarterly revenue and a reported net loss for the latest quarter. Market data indicated short-term upward momentum with a high Money Flow Index, though the price was trading above the upper Bollinger Band. Concurrently, news focused on advancements in colorectal cancer treatments targeting MSS/pMMR types, with several companies reporting positive preclinical and clinical trial data.

MSS news & sentiment

News coverage highlighted significant advancements in colorectal cancer treatments targeting MSS/pMMR types, with multiple companies reporting positive preclinical and clinical data. Social media discussion was not covered in the provided notes.

MSS technical picture

The stock showed short-term upward momentum, trading above its 10-day EMA and 50-day SMA, but remained significantly below its 200-day SMA. Momentum indicators suggested strong buying pressure and approached overbought territory, while the price briefly exceeded the upper Bollinger Band, indicating potential short-term overextension.

Fundamentals

The company's quarterly revenue decreased year-over-year, and it reported a net loss for the latest quarter. Annual revenue also declined from the prior fiscal year.

Factors discussed — upside

  • Strong short-term buying pressure indicated by MFI of 98.12
  • Current price above 10-day EMA and 50-day SMA
  • Positive developments in colorectal cancer treatment research targeting MSS/pMMR types

Factors discussed — risks

  • 8.6% year-over-year decrease in quarterly revenue
  • Net loss of $5.21 million for the quarter ending January 31, 2026
  • Stock price significantly below 200-day SMA
  • Current price trading above the upper Bollinger Band, suggesting overextension
  • Revenue trends
  • Profitability
  • Market momentum
  • Colorectal cancer treatments

Summary updated .

MSS technical indicators

Common technical indicators for MSS, computed from its daily closing prices.

IndicatorValueReading
50-day simple moving average1.71Price above
10-day exponential moving average1.67Price above
Relative strength index (14-day)64.73Neutral
MACD line (12/26/9)-0.0086Above its signal line
Bollinger bands (20-day, 2σ)1.32 – 1.90Price above the upper band

Analyses

Recent MSS.US analyses are locked — sign in to read them or generate a fresh one.

CaseDescriptionDate

Frequently asked questions

What is the bull case for Maison Solutions Inc.?
Recent analyses noted strong short-term buying pressure, with the current price trading above key moving averages and exhibiting positive momentum. Additionally, developments in colorectal cancer treatments targeting MSS/pMMR types were highlighted.
What are the risks for Maison Solutions Inc.?
The company's recent financial reports indicated a year-over-year decrease in quarterly revenue and a net loss for the latest quarter. Market data also showed the stock price trading above the upper Bollinger Band, suggesting potential overextension, and was significantly below its 200-day moving average.
Is Maison Solutions Inc. bullish or bearish?
Recent AI analyses of Maison Solutions Inc. examined factors on both sides. Discussed upside: Recent analyses noted strong short-term buying pressure, with the current price trading above key moving averages and exhibiting positive momentum. Additionally, developments in colorectal cancer treatments targeting MSS/pMMR types were highlighted. Discussed risks: The company's recent financial reports indicated a year-over-year decrease in quarterly revenue and a net loss for the latest quarter. Market data also showed the stock price trading above the upper Bollinger Band, suggesting potential overextension, and was significantly below its 200-day moving average. These are descriptive observations, not a recommendation.
What is the latest sentiment on Maison Solutions Inc.?
News coverage highlighted significant advancements in colorectal cancer treatments targeting MSS/pMMR types, with multiple companies reporting positive preclinical and clinical data. Social media discussion was not covered in the provided notes.
How does Market Scanner analyse Maison Solutions Inc.?
Every analysis of Maison Solutions Inc. runs the same five stages: four analysts read the market independently, a bull and a bear debate what they found, one agent turns the ruling into a position, three risk perspectives stress-test it, and a final agent writes the report. Market Scanner publishes what each stage does, with figures computed from the analyses on the platform rather than written in by hand.Read the methodology

Bundles used
gemini-low-v2

Run a fresh MSS.US analysis

Configure the ticker, model bundle and debate depth here — you only sign in at the end, and everything you picked comes with you.

Or read 1 earlier report



Most analyzed tickers